Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery
| Autor: | Izabela Siemińska, Kazimierz Węglarczyk, Marta Walczak, Agata Czerwińska, Radosław Pach, Mateusz Rubinkiewicz, Antoni Szczepanik, Maciej Siedlar, Jarek Baran |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Myeloid-derived suppressor cells (MDSCs)
Tumor recurrence TAN tumor associated neutrophils Cancer Research Neoplasms. Tumors. Oncology. Including cancer and carcinogens TAM tumor associated macrophages ARG-1 arginase-1 iNOS inducible NO synthase TAA tumor-associated antigen Colorectal cancer (CRC) PBMC peripheral blood mononuclear cells Oncology CRC colorectal cancer Treg T regulatory cells FMO fluorescence minus one T cell subsets MDSC myeloid derived suppressor cells RC254-282 Immunosuppression mAbs monoclonal antibodies Original Research |
| Zdroj: | Translational Oncology Translational Oncology, Vol 17, Iss, Pp 101346-(2022) |
| ISSN: | 1936-5233 |
| DOI: | 10.1016/j.tranon.2022.101346 |
| Popis: | Highlights • Colorectal cancer patients present increased level of all MDSCs populations in peripheral blood. • Eosinophilic MDSCs can be distinguished among PMN-MDSCs in the blood of colorectal cancer patients. • In patients with colorectal cancer Mo-MDSCs correlate negatively with tumor antigen associated CD8+ T cells. • In colorectal cancer patients an increase of circulating Mo-MDSCs after surgery may be associated with a higher risk of disease recurrence during a 5-year period. Colorectal cancer (CRC) is the third most common malignancy. Its development and progression is associated with natural immunosuppression related, among others, to myeloid derived suppressor cells (MDSCs). Overall, 54 patients in different stage of CRC, before any treatment were recruited into the study. The analysis included flow cytometry evaluation of blood MDSCs subsets, correlation their level with the tumor stage and T cell subsets. In the case of 11 patients, MDSCs level was evaluated before and 3 days after surgery, and these patients were monitored for cancer recurrence over 5 years. The results showed that frequency of circulating MDSCs subsets is increased significantly in CRC patients, with highest level detected in most advanced tumor stages. Moreover, only monocytic MDSCs (Mo-MDSCs) positively correlate with regulatory Treg, and negatively with tumor Her2/neu specific CD8+ T cells. Circulating MDSCs, in contrast to tumor resident (mostly Mo-MDSCs), are negative for PD-L1 expression. Additionally, after surgery the blood level of Mo-MDSCs increases significantly, and this is associated with tumor recurrence during a 5-year follow-up. In conclusion, Mo-MDSCs are pivotal players in CRC-related immunosuppression and may be associated with the risk of tumor recurrence after surgery. Graphical abstract Image, graphical abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|